Ertapenem and Faropenem against *Mycobacterium tuberculosis*: in vitro testing and comparison by macro and microdilution

Ximena Gonzalo†, Giovanni Satta†, Julio Ortiz Canseco2, Timothy D. McHugh2* and Francis Drobniewski3

Abstract

Background: Interest in carbapenems has been rising in the last few years due to the emergence of drug resistant tuberculosis. Ertapenem (ETP), given once a day parenteral, and faropenem (FAR), oral, have a better administration profile than meropenem (MEM), imipenem (IPM) and doripenem (DOR). The addition of amoxicillin-clavulanate (AMC) inhibits the hydrolysis by the carbapenemase present in *Mycobacterium tuberculosis* (MTB). The aim of this study was to determine the in vitro activity of ETP and FAR against susceptible and resistant clinical MTB strains by two widely use methodologies, the BACTEC960 MGIT and microdilution.

Results: 19 clinical isolates with different susceptibility profiles and H37Rv were included. Minimal inhibitory concentration (MIC) testing was performed using two methods of different concentrations of ETP and FAR with and without AMC. MIC50 was 2 and 8 for FAR with and without AMC by both methods. MIC90 was >16 and >8 by microdilution and MGIT respectively and did not change after AMC addition. 18/20 samples were resistant to the highest concentration of ETP, with and without AMC. Half of the samples had some susceptibility to FAR; addition of AMC further reduced the MIC level in seven isolates. 10/20 isolates showed susceptibility to FAR and the addition of AMC further reduced the MIC in 7 isolates. However, most of the MICs were near the limit of effectiveness (8 μg/mL). Resistance to FAR was associated with resistance to MEM (p = 0.04) but not to resistance profiles of other drugs, including M/XDR status.

Conclusions: The lack of ETP activity may be associated with its degradation, independent of carbapenemase, during incubation. No susceptibility pattern to traditional drugs can predict susceptibility to FAR and susceptibility testing is not routinely available. PK/PD studies are needed as reaching the concentrations tested in these experiments may be challenging. This work highlighted some of the limitations of carbapenem use. More evidence is needed to clarify their true impact (Continued on next page)
Background
Carbapenems have been known to be effective against non-tuberculous mycobacteria since the early 1990s [1] and act by inhibiting the L,D-transpeptidases [2]. However, inactivation by beta-lactamases, together with a highly effective and cheaper oral drug regimen for drug susceptible tuberculosis (TB), limited their use in treating TB. With the advent of drug resistant TB, especially multi drug and extremely drug resistant (MDR/XDR) forms, interest in carbapenems has increased based on preliminary in vitro results suggesting that they may be active at concentrations achievable in vivo and reports that suggest some carbapenems successfully contribute to cure [3] particularly for bacteria that are replicating [4].

Ertapenem (ETP) and imipenem (IPM) had been reported as being the most efficient L,D transpeptidase inhibitors of Mycobacterium tuberculosis (MTB) [2]. Other studies showed that meropenem (MEM) was the most stable carbapenem in the presence of the chromosomally encoded \textit{blaC} beta-lactamase [5] and that the addition of clavulanate, a beta-lactamase inhibitor, improved carbapenem activity, since this compound irreversibly inhibits the \textit{blaC} enzyme present in MTB [6, 7]. However, laboratory data on drug efficacy and specificity are variable, and a wide range of MICs for these drugs are reported [8, 9].

For many years, amoxicillin-clavulanate (AMC) has been considered a potentially useful anti-TB drug and classified by WHO as Group D (not part of the core MDR-TB regimen) [10] but there was little data to support its use. Clavulanate is only available in the UK combined with either amoxicillin or ticarcillin, with the former being the only one available orally. The addition of AMC to MEM showed a synergistic effect against MTB strains at concentrations easily achievable in vivo [8]. Unfortunately MEM requires intravenous administration three times a day and there remains the risk of carbapenem-resistance selection [11]. Other carbapenems have a better administration profile: ETP is given intravenously once a day and faropenem (FAR) is available for oral administration [12, 13].

FAR showed good killing activity in an ex vivo model of TB, using the laboratory strains Erdman and H37Rv [14]. An additional advantage of this compound is that it is stable in the presence of the MTB \textit{BlaC} enzyme, which means that it would remain active against those strains that become resistant to clavulanate [15]. ETP has also been shown to be active in vitro. However, testing is challenging since it degrades quickly at 37 °C [16].

Information regarding clinical use and outcomes in humans is starting to emerge, showing results suggestive of activity against MTB. The only observational study comparing imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB has suggested meropenem superiority and, currently, it is the carbapenem of choice when managing multi drug resistance [17].

The aim of this study was to determine the in vitro activity of ETP and FAR against susceptible and resistant clinical MTB strains by two widely use methodologies. The BACTEC960 MGIT system has several advantages over other methodologies, it is reliable for first and second line drug susceptibility testing, it offers automated incubation and reading and previous validation in numerous studies for the susceptibility testing of conventional and newer antimicrobials against MTB [18].

The microdilution method, on the other hand, is a flexible format that is widely used where MGIT is not available, in low throughput studies or in early stage drug development. For the same reasons and with the introduction of next generation sequencing (NGS) in the UK Mycobacterium Reference Services [19] microdilution methods have increased in prominence. This approach has been in use for several years for drug susceptibility testing (DST) in non-tuberculous Mycobacteria [19]. It is cheap and does not require additional instruments and it is usually read manually.

Results
The results of ETP and FAR testing (with and without AMC) are shown in Table 1. MIC50 was between 2 and 8 for FAR with and without clavulanate by both methods. MIC90 was >16 and >8 by microdilution and MGIT respectively and they did not change after the addition of clavulanic acid.

Eighteen out of twenty samples were resistant to the highest concentration of ETP tested, with and without AMC. Half of the samples tested had some degree of resistance or susceptibility to FAR and the addition of AMC further reduced the MIC level in six isolates.

Resistance or susceptibility to FAR was associated with resistance or susceptibility to meropenem (p = 0.04) but not to resistance profiles to other drugs, including M/XDR status.
Discussion

There were differences in MICs obtained by the two methods used in this study. Generally, the microdilution method produced lower MICs. This may be associated with the differences in the methodologies.

ETP showed no activity against strains tested on the MGIT system (even against fully susceptible strains) and activity against 5 isolates in the microdilution model. The consistent lack of activity is likely to be an artefact associated with the reported phenomenon of ETP degradation in vitro [16]. Given the slow replication of MTB, this leads to a challenging situation in testing where the antibiotic is possibly degraded before killing or inhibiting bacterial growth. This is highlighted by the difference in the two methods where a positive readout in the MGIT would typically be at 2 to 33 days [20] whereas the microdilution method is after 7 days [21]. Some authors have also suggested the daily addition of antibiotics to this experimental set up [22] but this would hamper the evaluation of the dose tested and it would increase the risk of contamination as well as posing a repeated risk for the operator when working with M/XDR-TB. The addition of AMC did not translate into significant improvements in susceptibility. Although, ETP has been reported as useful in the treatment of TB previously as part of combination therapy, its role remains unclear [3, 23]. Previous laboratory studies reported the ETP MIC at 4 μg/mL [3].

It is also important to further discuss the PK/PD of carbapenems when evaluating their efficacy. Carbapenems have a time-dependent mechanism of killing and exhibit a bacteriostatic effect when at least 20% of the exposure time is above the MIC. The bactericidal effect is achieved when the exposure time above the MIC is at least 40% [24]. A clinical study evaluating ETP pharmacokinetics in 12 patients with MDR or XDR TB found that the C\text{max} was 127.5 μg/mL and the half-life was 2.4 h [25]. Considering that ETP requires only one daily dose, the blood concentration should remain above the theoretical MIC of 4 μg/mL for at least 8 h and additional administrations may be required if clinical isolates have a higher MIC. Similar data on FAR are still lacking, including studies on the early bactericidal activity, but some clinical trials are currently ongoing [26].

Stability is not a problem for FAR as it is thermo-stable at 37 degrees [27]. Ten clinical isolates (out of 20) showed different degrees of susceptibility to FAR and the addition of AMC further reduced the MIC in 6 clinical isolates. This is in line with previous experiments with other carbapenems, in particular MEM [8]. However, most of the MICs were very close to 8 μg/mL, which suggests we are reaching the limit of effectiveness. The current breakpoint for Gram positive bacteria is 2 μg/mL and 8 μg/mL for Gram negative microorganisms [28]. FAR did show some limited activity (MIC of 4 or higher) in strains completely resistant to MEM (MIC of 32 or higher). However, the five isolates fully susceptible to first line antituberculous drugs were completely resistant at the highest concentration of FAR used. This highlights a major issue of unpredictability and explains its limited use in clinical practice as no susceptibility pattern to traditional drugs can predict susceptibility to FAR and susceptibility testing is not available. In addition, further studies are still needed to assess which antibiotic level is actually achievable in the blood (and in the lung parenchyma) after the oral administration of FAR as reaching the concentrations tested in these experiments may be challenging.

Limitations of our study include the limited number of strains used, the analysis of in vitro data and the focus on the synergistic effect with AMC only. Other authors have also proposed the use of rifampin to provide additional synergy to carbapenems in the treatment of MTB and M. abscessus [29]. Further animal models or direct studies from patients with XDR strains may also be necessary to evaluate the real in vivo impact of complex treatment regimens including carbapenems on both the PK/PD of the drugs and their bactericidal effect.

The increasing global incidence of drug resistant TB demands additional therapeutic options. Although carbapenems are promising agents, this work has highlighted some of the limitations of their use. Information regarding clinical use and outcomes in humans is starting to emerge, showing results suggestive of activity against MTB. However, the contribution of the beta-lactam to the outcomes remains difficult to ascertain [26, 27]. Current opinions suggest that until more evidence becomes available, these drugs should be considered companion drugs rather than effective anti-TB agents [28], particularly in light of the administration route and higher cost associated to their use. Emergence of carbapenem resistance amongst gut microbiota is also an undesirable consequence of the use of these antibiotics and it is associated not only with the use of the drug but also with the duration of the exposure, that in the case of tuberculosis, is usually prolonged [30]. More evidence is needed to clarify the true impact of carbapenems in both TB treatment and outcome and as well as the financial burden, complications and microbiota ecological changes associated with their use to justify their re-classification as effective anti-TB agents.

Conclusions

The lack of ETP activity may be associated with its degradation during incubation and a significant level of resistance was found in our experiments.

FAR may represent a more promising option as half of the isolates showed susceptibility and the addition of AMC further reduced the MIC in 7 isolates. However, most of the MICs were near the limit of effectiveness (8 μg/mL).
Table 1 | MICs of the isolates against FAR and ETP with and without AMC.

| Strain number (n=20) | Microdil FAR | MGIT FAR | Microdil FAR+clav | MGIT FAR+clav | Microdil ETP | MGIT ETP | Microdil ETP+clav | MGIT ETP+clav |
|---------------------|--------------|----------|-------------------|---------------|--------------|----------|-------------------|--------------|
| 11:156              | 2            | 8        | 4                 | 2             | >32          | >16      | >32               | >16          |
| 11:368              | >16          | >8       | >16               | >8            | >32          | >16      | >32               | >16          |
| 07:116              | 4            | 4        | 4                 | 1             | >32          | 16       | >32               | 16           |
| 11:191              | 8            | >8       | 8                 | >8            | >32          | >16      | >32               | >16          |
| 11:136              | 8            | 8        | 8                 | 4             | >32          | >16      | >32               | >16          |
| 03:013              | 8            | 8        | 8                 | 4             | >32          | >16      | >32               | >16          |
| 05:094              | 4            | 4        | 16                | 4             | >32          | >16      | >32               | >16          |
| 03:39               | 16           | 8        | 4                 | 4             | >32          | >16      | >32               | >16          |
| H37Rv               | 2            | >8       | 4                 | >8            | 8            | >16      | 16                | >16          |
| 04:18               | 0.5          | 4        | <0.125            | 4             | >32          | >16      | >32               | >16          |
| 324                 | 2            | >8       | 0.5               | >8            | 8            | >16      | 16                | >16          |
| 333                 | 2            | >8       | 0.5               | >8            | 8            | >16      | 4                 | >16          |
| 346                 | 1            | 8        | 0.5               | 8             | 4            | >16      | 16                | >16          |
| 347                 | >16          | >8       | >16               | >8            | >32          | >16      | >32               | >16          |
| 401                 | >16          | >8       | >16               | >8            | >32          | >16      | >32               | >16          |
| 408                 | >16          | >8       | >16               | >8            | >32          | >16      | >32               | >16          |
| 443                 | >16          | >8       | >16               | >8            | >32          | >16      | >32               | >16          |
| 548                 | >16          | >8       | >16               | >8            | >32          | >16      | >32               | >16          |
| 421                 | >16          | >8       | >16               | >8            | >32          | >16      | >32               | >16          |
| 433                 | 0.25         | >8       | <0.125            | >8            | 2            | >16      | 1                 | >16          |

Concentrations are expressed in mg/L. Clavulanate was used at a fixed concentration of 2.5 mg/L. FAR Faropenem, ETP Ertapenem, clav Clavulanate, microdil Microdilution, MGIT Mycobacterium Growth Incubator Tube. LJ Lowenstein Jensen. Green shading: concentrations achievable in vivo; orange shading: concentrations above those achievable in vivo with current dosing recommendations.
No susceptibility pattern to traditional drugs can predict susceptibility to FAR and susceptibility testing is not routinely available. PK/PD studies are needed as reaching the concentrations tested in these experiments may be challenging.

This work highlighted some of the limitations of carbapenem use. More evidence is needed to clarify their true impact in TB treatment and outcome, considering the financial burden, complications and microbiota changes associated with their use.

Methods
Selection of isolates
Twenty isolates in total (9 UK clinical isolates, 10 Russian clinical isolates plus H37Rv) were tested including drug susceptible, MDRTB and XDRTB. A full profile of the strains’ susceptibility, including meropenem, can be found in Table 2.

Susceptibility testing
BACTEC960 MGIT system
Minimal inhibitory concentration testing was performed using the MGIT [18]. Four different concentrations of ETP and FAR were tested with and without the addition of AMC. These concentrations were selected based on previous pharmacokinetics/pharmacodynamics (PK/PD) data [12, 31]. All drugs were from Sigma-Aldrich (Dorset, UK) as either sodium (ertapenem/faropenem) or potassium (amoxicillin/clavulanate) salts and diluted in sterile water. The AMC potassium powder comes in a ratio of 2:1 and it was diluted to reach a final concentration of clavulanate of 2.5 μg/ml. A summary of the different concentrations used is provided in Table 3.

Microdilution
Microdilution testing was performed as previously described [21]. Briefly, 8 different concentrations of ERT and FAR were tested with and without the addition of AMC. These concentrations were selected based on previous pharmacokinetics/pharmacodynamics (PK/PD) data [12, 31]. All drugs were from Sigma-Aldrich (Dorset, UK). ERT and FAR were diluted in a mix of DMSO and distilled water and AMC were diluted in distilled water. A summary of the different concentrations used is provided in Table 3.

The concentrations tested were chosen based on previously published PK/PD data and the level of antibiotic

| Strain | Phenotypical resistance profile | Meropenem clavulanate MIC (μg/ml) | Notes |
|--------|-------------------------------|-----------------------------------|-------|
| 03:013 S | 32 | MonoR |
| 03:039 H | 16 | MonoR |
| 04:018 H, R, clari, ethi | Failed | MDR |
| 05:004 Fully susceptible | 8 | |
| 07:116 H, ethi | 4 | PolyR |
| 11:136 S,H,R | >32 | MDR |
| 11:156 S,H,R | 4 | MDR |
| 11:191 H | 16 | MonoR |
| 11:368 S,H,R | >32 | MDR |
| 324 Fully susceptible | 8 | |
| 333 S,H,R | 2 | MDR |
| 346 S,H,R | 2 | MDR |
| 347 Fully susceptible | >32 | |
| 401 H,R | >32 | MDR |
| 408 S, H, R | >32 | MDR |
| 443 Fully susceptible | >32 | |
| 548 N/A* | >32 | XDR |
| 421 S, H, R, EMB, CAP, Moxi | >32 | XDR |
| 433 S, H, R, EMB, PYR, CAP, Moxi | 8 | XDR |
| H37Rv Fully susceptible | 2 | Control reference strain |

MDR Multi-Drug resistant; XDR Extensively drug resistance; MonoR Resistant to one drug only; PolyR Resistant to more than one drug other than H/R. The resistance profile is shown in the second column, with a variety of fully susceptible, MonoR, MDR and XDR samples (S Streptomycin, H Isoniazid, R Rifampicin, Clari Clarithromycin, Ethi Ethionamide, EMB Ethambutol, CAP=Capreomycin, Moxi = Moxifloxacin, PYR = Pyrazinamide). The MIC against Meropenem/clavulanate is also shown.
achievable in the blood with the currently licensed dosing regimens [12, 31].

**Controls**
The reference strain H37Rv was used as a control strain. Growth controls without the addition of any drug were used in the MGIT testing as per manufacturer instructions. Positive (H37Rv without any drug) and negative (7H9 broth with no bacteria) controls were used in the microdilution method.

**Abbreviations**
MEM: Meropenem; ETP: Ertapenem; FAR: Faropenem; AMC: Amoxicillin-clavulanate; S: Streptomycin; H: Isoniazid; R: Rifampicin; Clari: Clarithromycin; Pyr: Pyrazinamide; Tuberculosis: TB; M TB: Mycobacterium tuberculosis; MDR: Multi drug resistant; XDR: Extremely drug resistant; MIC: Minimum inhibitory concentration; MGIT: Mycobacterium growth incubator tube; PK/PD: Pharmacokinetics/pharmacodynamics

**Acknowledgements**
The authors wish to thank Ms. Agnieszka Broda for her cooperation and support in the logistics required to perform the experiments.

**Authors’ contributions**
XG and GS have equally contributed as joint first authors. GS, TMcH, XG & FD conceived and designed the study. GS, XG & JOC performed the microbiological assays. All authors contributed to the analysis of data and conception of the study. GS, TMcH, XG & JOC performed the microbiological assays. All authors contributed to the analysis of data and conception of the study. GS, TMcH, XG & FD performed the statistical analysis.

**Funding**
All this work was funded internally with departmental budgets and was independent of the study design and delivery.

**Availability of data and materials**
Are available on request to the corresponding author TMcH.

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Competing interests**
The authors have no competing interests to declare.

**Author details**
1Department of Infectious Diseases, Section Adult Infectious Diseases, Imperial College London, London W12 OHS, United Kingdom. 2Centre for Clinical Microbiology, Division of Infection & Immunity, University College London, Royal Free Campus, Rowland Hill Street, London NW3 2QG, UK. 3Imperial College London, Department of Infectious Diseases, Section Adult Infectious Diseases, Imperial College London, 8th Floor, Commonwealth Building, Hammersmith Campus, Du Cane Rd, Shepherd’s Bush, London W12 0HS, United Kingdom.

**Table 3** Concentrations of ertapenem and faropenem tested

|                  | 8-16 | 2-18 | 4-9 | 8-16 | 2-18 | 4-9 |
|------------------|------|------|-----|------|------|-----|
| ETP (µg/mL)      | 16-8 | 16-8 | 16-8 | 16-8 | 16-8 | 16-8 |
| MIC (µg/mL)      | 8-4  | 2-1  | 4-2  | 16-8 | 2-1  | 8-4  |
| CIP (µg/mL)      | 0.25 | 0.25 | 0.5  | 1    | 2    | 4   |
| CIP (µg/mL)      | 0.05 | 0.05 | 0.1  | 0.2  | 0.4  | 0.8 |
| CIP (µg/mL)      | 0.05 | 0.05 | 0.1  | 0.2  | 0.4  | 0.8 |
| CIP (µg/mL)      | 0.05 | 0.05 | 0.1  | 0.2  | 0.4  | 0.8 |

Different concentrations of ETP and FAR were tested with and without the addition of AMC (2.5 µg/mL)

**Received:** 31 May 2020 **Accepted:** 20 August 2020

**Published online:** 31 August 2020

**References**
1. Yew WW, Kwan SY, Wong PC, Lee J. Ofloxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chelonae lung infections. Tubercle. 1990;71(2):131–3.
2. Cordilott M, Dubee V, Triboulet S, Dubost L, Marie A, Hugonnet JE, et al. In Vitro Cross-Linking of Mycobacterium tuberculosis Peptidoglycan by L-D Transpeptidases and Inactivation of These Enzymes by Carbapenems. Antimicrob Agents Chemother. 2013;57(12):5940–5.
3. Vesris N, Truffot C, Mainardi JL, Jarlier V. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother. 2011;55(6):2597–600.
4. Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, Toner M, et al. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science. 2011;333(6064):100–4.
5. England K, Boshoff HM, Arora K, Weiner D, Dayao E, Schimel D, et al. Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother. 2012;56(6):3384–7.
6. Hugonnet JE, Tremblay LW, Boshoff HL, Barry CE 3rd, Blanchard JS. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science. 2009;323(5918):1215–8.
7. Dubee V, Triboulet S, Mainardi JL, Etche-Caquelieu M, Gutmann L, Marie A, et al. Inactivation of Mycobacterium tuberculosis LD-Transpeptidase (Mt1) by Carbapenems and Cephalosphorins. Antimicrob Agents Chemother. 2012;56(8):4189–95.
8. Gonzalo X, Drobniewski F. Is there a place for beta-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J Antimicrob Chemother. 2013;68(2):366–7.
9. Jaganath D, Lamichhane G, Shah M. Carbapenems against Mycobacterium tuberculosis: a review of the evidence. Int J Tuberc Lung Dis. 2016;20(11):1436–47.
10. World Health Organization. Technical Report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. Geneva: WHO; 2018.
11. McLaughlin M, Advincula MR, Malczynski M, Qi C, Bolon M, Scheetz MH. Activity of carbapenems combined with clavulanate against murine tuberculosis. Antimicrob Agents Chemother. 2015;59(10):5131–3.
12. Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG. Correlations of antibiotic use and carbapenem resistance in enterobacteriaceae. Antimicrob Agents Chemother. 2013;57(10):5131–3.
13. Schurek KN, Wiebe R, Karlowsky JA, Rubinstein E, Hoban DJ, Zhanel GG. Faropenem: review of a new oral penem. Expert Rev Anti-Infect Ther. 2007; 5(2):185–98.
14. Committee JF. British National Formulary. 71st ed ed. London: BMJ Group and Pharmaceutical Press; 2016.
15. Dhar N, Dubee V, Ballell L, Cuinet G, Hugonnet JE, Signorino-Gelo F, et al. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable beta-lactam antibiotic. Antimicrob Agents Chemother. 2013;59(2):1308–19.
16. Soroka D, Lu de la sierra-Gallay I, Dubee V, Triboulet S, van Tilbeurgh H, Compain F, et al. hydrolysis of clavulanate by Mycobacterium tuberculosis beta-lactamase BlAC harboring a canonical SDN motif. Antimicrob Agents Chemother. 2015;59(9):5714–20.
17. Srivastava S, van Rijn SP, Wessels AM, Affenaar JW, Gumbo T. Susceptibility testing of antibiotics that degrade faster than the doubling time of slow-
growing mycobacteria: Ertapenem sterilizing effect versus Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60(5):3193–5.

17. Tiberi S, Sotgiu G, D’Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, et al. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB. Eur Respir J. 2016;47(6):1756–66.

18. Krüüner A, Yates MD, Drobniewski FA. Evaluation of MGT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of <em>Mycobacterium tuberculosis</em> (H37Rv). J Clin Microbiol. 2006;44(3):811–8.

19. Public Health England. National Mycobacterium Reference Service-South (NWRS-south) user handbook. In: service-south NMR, editor. London: PHE publications; 2019.

20. Somoskovi A, Clobridge A, Larsen SC, Sinyavskyi O, Surucuoglu S, Parsons LM, et al. Does the MGT 960 system improve the turnaround times for growth detection and susceptibility testing of the Mycobacterium tuberculosis complex? J Clin Microbiol. 2006;44(6):2314–5.

21. Coban AY, Billinci B, Ekinci B, Durupinar B. Drug susceptibility testing of Mycobacterium tuberculosis by the broth microdilution method with 7H9 broth. Mem Inst Oswaldo Cruz. 2004;99:111–3.

22. Watt B, Edwards JR, Rayner A, Grindey AJ, Harris G. In vitro activity of meropenem and imipenem against mycobacteria: development of a daily antibiotic dosing schedule. Tuberc Lung Dis. 1992;73(3):134–6.

23. Tiberi S, D’Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J. 2016;47(1):333–6.

24. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenem. Drugs. 2007;67(7):1027–52.

25. van Rijn SP, van Altena R, Akkerman OW, van Soolingen D, van der Laan T, de Lange WC, et al. Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis. Eur Respir J. 2016;47(4):1229–34.

26. Diacon AH, van der Merwe L, Barnard M, van Grote-Bidlingmaier F, Lange C, Garcia-Basteiro AI, et al. Beta-lactams against tuberculosis–new trick for an old dog? N Engl J Med. 2016;375(4):393–4.

27. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastometric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46(8):2327–32.

28. "The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 9.0, 2019. http://www.eucast.org)."

29. Kaushik A, Makkar N, Pandey P, Parish N, Singh U, Lamichhane G. Carbapenems and rifampin exhibit synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob Agents Chemother. 2015;59(10):6561–7.

30. Pano Pardo JR, Serrano Villar S, Ramos Ramos JC, Pintado V. Infections caused by carbapenemase-producing Enterobacteriaceae: risk factors, clinical features and prognosis. Enferm Infec Microbiol Clin. 2014;32(Suppl 4):41–8.

31. Nix DE, Majumdar AK, DNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother. 2004;53(Suppl 2):ii23–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.